CoChat

Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map

Kumar, Jai, Memon, Roha Saeed, Shahid, Izza, Rizwan, Tehlil, Zaman, Maryam, Menezes, Ritesh G., Kumar, Sarwan, Siddiqi, Tariq Jamal, Usman, Muhammad Shariq · 2021 · Digestive and Liver Disease
Cited by 68

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

BACKGROUND The efficacy of antidiabetic agents for the treatment of non-alcoholic fatty liver disease (NAFLD) remains unclear. AIM To conduct a meta-analysis to study the efficacy of pioglitazone and three novel anti-diabetic agents: glucagon-like peptide-1 (GLP-1) agonists, sodium-glucose co-transporter-2 (SGLT2) inhibitors, and dipeptidyl-peptidase-4 (DPP4) inhibitors in treating NAFLD. METHODS Online databases were searched in May 2020 for randomized clinical trials. Results from random-effects meta-analysis are presented as weighted mean differences (WMDs) or standard mean differences (SMDs) and corresponding 95% confidence intervals (CIs). RESULTS Twenty-six studies (n=946 NAFLD patients) were included. Reductions in ALT were seen with all four drugs: pioglitazone (MD -38.41, p<0.001), SGLT2 inhibitors (MD -16.17, p<0.001), GLP-1 agonists (MD -27.98, p=0.04) and DPP-4 inhibitors (MD -7.41, p<0.001). Pioglitazone (SMD -1.01; p<0.001) and GLP-1 agonists (SMD -2.53, p=0.03) also demonstrated significant improvements in liver steatosis. SGLT2 inhibitors (SMD -4.64, p=0.06) and DPP-4 (SMD -2.49, p=0.06) inhibitors trended towards reduced steatosis; however, these results were non-significant. CONCLUSION Pioglitazone demonstrates significant improvements in transaminases and liver histology in both diabetic and non-diabetic NAFLD patients. Early evidence from diabetic NAFLD patients suggests that novel antidiabetics may lead to improvements in liver enzymes and hepatic steatosis, and this should encourage further research into possible utility of these drugs in treating NAFLD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.dld.2020.08.021

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 13

  1. Ballestri, 2016, Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis, J Gastroenterol Hepatol, 31, 936, 10.1111/jgh.13264 · DOI · Paper page
  2. Mantovani, 2018, Nonalcoholic fatty liver disease and risk of incident type 2 diabetes mellitus: a meta-analysis, Diabetes Care, 41, 372, 10.2337/dc17-1902 · DOI · Paper page
  3. Sattar, 2018, Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial, Diabetologia, 61, 2155, 10.1007/s00125-018-4702-3 · DOI · Paper page
  4. Ito, 2017, Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial, Diabetes Care, 40, 1364, 10.2337/dc17-0518 · DOI · Paper page
  5. Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557 · DOI · Paper page
  6. Razavizade, 2013, The effect of pioglitazone and metformin on liver function tests, insulin resistance, and liver fat content in nonalcoholic Fatty liver disease: a randomized double blinded clinical trial, Hepat Mon, 13, e9270, 10.5812/hepatmon.9270 · DOI
  7. Lutchman, 2007, The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis, Hepatology, 46, 424, 10.1002/hep.21661 · DOI · Paper page
  8. Shibuya, 2018, Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non‐alcoholic fatty liver disease: a prospective randomized controlled pilot study, Diabetes Obes Metab, 20, 438, 10.1111/dom.13061 · DOI · Paper page
  9. Cui, 2016, Sitagliptin vs. placebo for non-alcoholic fatty liver disease: a randomized controlled trial, J Hepatol, 65, 369, 10.1016/j.jhep.2016.04.021 · DOI · Paper page
  10. Deng, 2017, Short article: a randomized-controlled study of sitagliptin for treating diabetes mellitus complicated by nonalcoholic fatty liver disease, Eur J Gastroenterol Hepatol, 29, 297, 10.1097/MEG.0000000000000780 · DOI · Paper page
  11. Macauley, 2015, Effect of vildagliptin on hepatic steatosis, The J Clin Endocrinol Metab, 100, 1578, 10.1210/jc.2014-3794 · DOI · Paper page
  12. Alghaith, 2019, PDG2 efficacy of pioglitazone in improving liver histology scores of patients with non-alcoholic fatty liver disease: a systematic-review and meta-analysis, Value Health, 22, S163, 10.1016/j.jval.2019.04.681 · doi:10.1016/j.jval.2019.04.681
  13. Prat, 2018, The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD), Hormones, 17, 219, 10.1007/s42000-018-0021-9 · DOI

Cited by

Metadata

Authors
Kumar, J., Memon, R. S., Shahid, I., Rizwan, T., Zaman, M., Menezes, R. G., Kumar, S., Siddiqi, T. J., & Usman, M. S.
Venue
Digestive and Liver Disease
Publisher
Elsevier BV
Published
2021-01
Volume
53
Issue
1
Pages
44-51
ISSN
1590-8658 (ISSN-L)
OpenAlex
W3083948332
Cited by
68
References
8
FWCI
2.64
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.